Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)

NCT04860960 is registered in ClinicalTrials.gov with Cyclo Therapeutics, Inc. as lead sponsor.

NCT NCT04860960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of 2000mg/kg of Trappsol®Cyclo™ (Hydroxypropyl-B-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients With Niemann-Pick Disease Type C1 (TransportNPC)
Lead sponsor
Cyclo Therapeutics, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
July 20, 2021
Completion date
June 30, 2026
Enrollment
94 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

niemann-pick disease, type c1